L2 Diagnostics LLC

Delivery of a Candidate Agtriovx Malaria Vaccine by Thermostable Microneedle Patches - Abstract Malaria Remains One of the Deadliest Infectious Diseases. Although Much Progress Has Been Made in the Fight Against Malaria, a Highly Effective and Durable Vaccine Is Not Available. New Vaccine Candidates and Improved Delivery Strategies Are Urgently Needed. We Recently Demonstrated That a Anopheles Gambiae Mosquito Saliva Protein, Called Agtrio, Is a Viable Mrna-lnp Vaccine in Mice, Either as a Single Agent or in Synergistic Combination With the Target of the Currently Marketed RTS,S/AS01 Vaccine (mosquirix). This Project Addresses the Real-world Problem of Delivery of an Antimalaria Mrna Vaccine in Endemic, Resource-poor Countries Where Cold- Chain Storage Hugely Limits Deployment of Mrna Vaccines. Our Product Solution Employs Novel Dissolvable Microneedle Patches (MNPS) to Administer Our Agtrio Mrna-lnp Formulation. These Microneedle Patches Can Be Self-applied, Are Less Painful Than Intramuscular Injection, Produce No Sharps Waste, Have a Long-term Shelf Life for Up to Six Months at Room Temperature, and Can Be Produced at Scale With Robust Methods. the Single Specific Aim of This Project Is to Produce a Novel Agtriovx MNP That Protects Against Malaria in a Mouse Model in Preparation for Pre-clinical and Human Clinical Studies at a Future Phase.